Search results
Showing 1 to 15 of 16 results for liraglutide -victoza-
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)
NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA749
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)
This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.
Liraglutide for the treatment of type 2 diabetes mellitus (TA203)
This guidance has been updated and replaced by NICE guideline NG28.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by NICE
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England, NICE has said in draft guidance.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use, a NICE committee has said.